Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma.
Adult
Aged
Antimetabolites, Antineoplastic
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
Central Nervous System Neoplasms
/ drug therapy
Cytarabine
/ administration & dosage
Disease-Free Survival
Female
Follow-Up Studies
Humans
Injections, Intraventricular
Karnofsky Performance Status
Lymphoma
/ drug therapy
Male
Methotrexate
/ administration & dosage
Middle Aged
Outcome Assessment, Health Care
Pilot Projects
Survival Analysis
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
08 12 2020
08 12 2020
Historique:
received:
04
05
2020
accepted:
23
07
2020
pubmed:
30
9
2020
medline:
16
12
2020
entrez:
29
9
2020
Statut:
ppublish
Résumé
To determine whether a fraction of patients with primary CNS lymphoma (PCNSL) had been cured by systemic and intraventricular methotrexate- and cytarabine-based chemotherapy (Bonn protocol) after a very long-term follow-up of nearly 20 years. Sixty-five patients (median age 62 years, range 27-75; median Karnofsky performance score 70, range 20-90) had been treated with systemic and intraventricular polychemotherapy without whole brain radiotherapy from September 1995 until December 2001. All patients still alive in 2019 were contacted and interviewed on their current life situation. Median follow-up for surviving patients was 19.6 years (17.5-23.3 years). Out of 65 patients, 11 (17%) were still alive. Six of those never experienced any relapse. For the whole study population, median overall survival (OS) was 4.4 years (95% confidence interval [CI] 2.9-5.9); for patients ≤60 years, 11.0 years (95% CI 4.8-17.0). The 10-year OS rate for the entire cohort was 29% and the estimated 20-year OS rate was 19%. Four late relapses were observed after 9.8, 10.3, 13.3, and 21.0 years. At a median follow-up of 19.6 years, 17% of patients were alive and free of tumor; however, even after response for decades, an inherent risk of relapse, either systemic or cerebral, characterizes the biology of PCNSL. This work provides Class III evidence that PCNSL treatment with methotrexate-based polychemotherapy including intraventricular therapy is associated with long-term disease control in some patients.
Identifiants
pubmed: 32989105
pii: WNL.0000000000010949
doi: 10.1212/WNL.0000000000010949
pmc: PMC7734926
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Cytarabine
04079A1RDZ
Methotrexate
YL5FZ2Y5U1
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3138-e3144Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Cancer Sci. 2019 Jan;110(1):401-407
pubmed: 30353605
Lancet Haematol. 2017 Nov;4(11):e510-e523
pubmed: 29054815
J Clin Oncol. 2019 Apr 1;37(10):823-833
pubmed: 30785830
J Clin Oncol. 2013 Sep 1;31(25):3061-8
pubmed: 23569323
Neuro Oncol. 2011 May;13(5):525-9
pubmed: 21372070
J Clin Neurosci. 2011 Nov;18(11):1554-5
pubmed: 21868233
J Clin Oncol. 2009 Jul 20;27(21):3503-9
pubmed: 19451444
Neurology. 2013 Jul 2;81(1):84-92
pubmed: 23685932
J Clin Oncol. 2013 Nov 1;31(31):3971-9
pubmed: 24101038
Neurology. 2005 Oct 11;65(7):1129-31
pubmed: 16217075
Neuro Oncol. 2019 Feb 19;21(3):296-305
pubmed: 30418592
J Neurooncol. 2005 Sep;74(2):201-5
pubmed: 16193393
Blood. 2015 Feb 26;125(9):1403-10
pubmed: 25568347
Lancet Haematol. 2016 Aug;3(8):e388-97
pubmed: 27476790
J Clin Oncol. 1998 Mar;16(3):859-63
pubmed: 9508166
Neurol Res Pract. 2019 Jun 20;1:17
pubmed: 33324883
Arch Neurol. 2005 Oct;62(10):1595-600
pubmed: 16216945
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):408-13
pubmed: 16198065
Ann Neurol. 2010 Feb;67(2):182-9
pubmed: 20225195
Neurology. 2004 Jul 13;63(1):167-9
pubmed: 15249632
J Clin Oncol. 2003 Dec 15;21(24):4489-95
pubmed: 14597744